A Phase 1 interventional study of AZD3974 and Placebo in Healthy Participants, sponsored by AstraZeneca. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.
This is a first in human, randomized, single-blind, placebo-controlled study. It consists of two parts.
Part A (single ascending dose - SAD): This study part will enroll six cohorts (plus two optional additional cohorts) of healthy participants (Part A1), three cohorts (plus one optional additional cohort) of healthy Japanese participants (Part A2) and one cohort (plus one optional additional cohort) of healthy Chinese participants (Part A3). Cohort 3 of Part A1 will be extended to evaluate the effect of food intake on the PK of AZD3974. In Part A (all cohorts), participants will receive a single dose of AZD3974 or placebo.
Part B (Multiple Ascending Dose - MAD): This study part will consist of four cohorts (plus two optional additional cohorts) of healthy participants (Part B1) and one cohort (plus one optional additional cohort) of healthy Japanese participants (Part B2). In all Part B cohorts, participants will receive multiple doses of AZD3974 or placebo.
Both Part A and Part B will comprise of:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants will receive a single dose of AZD3974 - Dose 1
Drug: AZD3974
Healthy participants will receive a single dose of AZD3974 - Dose 2
Drug: AZD3974
Healthy participants will receive two single doses of AZD3974 - Dose 3
Drug: AZD3974
Healthy participants will receive a single dose of AZD3974 - Dose 4
Drug: AZD3974
Healthy participants will receive a single dose of AZD3974 - Dose 5
Drug: AZD3974
Healthy participants will receive a single dose of AZD3974 - Dose 6
Drug: AZD3974
Healthy participants will receive a single dose of AZD3974
Drug: AZD3974
Healthy participants will receive a single dose of AZD3974
Drug: AZD3974
Healthy participants will receive a single dose of matching placebo to AZD3974
Other: Placebo
Healthy participants will receive two single doses of matching placebo to AZD3974
Other: Placebo
Healthy Japanese participants will receive a single dose of AZD3974
Drug: AZD3974
Healthy Japanese participants will receive a single dose of AZD3974
Drug: AZD3974
Healthy Japanese participants will receive a single dose of AZD3974
Drug: AZD3974
Healthy Japanese participants will receive a single dose of AZD3974
Drug: AZD3974
Healthy Japanese participants will receive a single dose of matching placebo to AZD3974
Other: Placebo
Healthy Chinese participants will receive a single dose of AZD3974
Drug: AZD3974
Healthy Chinese participants will receive a single dose of AZD3974
Drug: AZD3974
Healthy Chinese participants will receive a single dose of matching placebo to AZD3974
Other: Placebo
Healthy participants will receive multiple doses of AZD3974
Drug: AZD3974
Healthy participants will receive multiple doses of AZD3974
Drug: AZD3974
Healthy participants will receive multiple doses of AZD3974
Drug: AZD3974
Healthy participants will receive multiple doses of AZD3974
Drug: AZD3974
Healthy participants will receive multiple doses of AZD3974
Drug: AZD3974
Healthy participants will receive multiple doses of AZD3974
Drug: AZD3974
Healthy participants will receive multiple doses of matching placebo to AZD3974
Other: Placebo
Healthy Japanese participants will receive multiple doses of AZD397
Drug: AZD3974
Healthy Japanese participants will receive multiple doses of matching placebo to AZD3974
Drug: AZD3974
Healthy Japanese participants will receive multiple doses of matching placebo to AZD3974
Other: Placebo
AZD3974 will be administered as an oral solution.
Placebo will be administered as an oral solution.
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
To assess the safety and tolerability of AZD3974 following oral administration of single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Upto Day 7; Part A1 Cohort 3: Upto Day 10; Part B: Upto Day 14
Part A and Part B: Plasma concentrations of AZD3974
To characterize the plasma concentrations of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Plasma concentrations of AZD3974
To assess the impact of food (fed) on the single-dose plasma concentrations of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Urine concentrations of AZD3974
To characterize the urine concentration of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.
Time frame: Part A: Day 1; Part B: Day 1 and Day 7
Part A1-Cohort 3: Urine concentrations of AZD3974
To assess the impact of food (fed) on the single-dose urine concentrations of AZD3974
Time frame: Day 1 and Day 3
Part A and Part B: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A: Area under concentration-time curve from time 0 to infinity (AUCinf)
To characterize the PK of AZD3974 following single ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Day 1 to Day 2
Part A1-Cohort 3: Area under concentration-time curve from time 0 to infinity (AUCinf)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Maximum observed drug concentration (Cmax)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Maximum observed drug concentration (Cmax)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Time to reach maximum observed concentration (tmax)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Time to reach maximum observed concentration (tmax)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Terminal elimination half-life (t½λz)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Terminal elimination half-life (t½λz)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Apparent total body clearance (CL/F)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Apparent total body clearance (CL/F)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Apparent volume of distribution based on the terminal phase (Vz/F)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Apparent volume of distribution based on the terminal phase (Vz/F)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Individual and cumulative amount of unchanged drug excreted into urine from time t0 to time tlast [Ae(0-last)]
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Day 1; Part B: Day 1 and Day 7
Part A1-Cohort 3: Individual and cumulative amount of unchanged drug excreted into urine from time t0 to time tlast [Ae(0-last)]
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 and Day 3
Part A and Part B: Individual and cumulative percentage of dose excreted unchanged in urine from time t0 to tlast [fe(0-last)]
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Day 1; Part B: Day 1 and Day 7
Part A1-Cohort 3: Individual and cumulative percentage of dose excreted unchanged in urine from time t0 to tlast [fe(0-last)]
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 and Day 3
Part A and Part B: Renal clearance (CLR)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants
Time frame: Part A: Day 1; Part B: Day 1 and Day 7
Part A1-Cohort 3: Renal clearance (CLR)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 and Day 3
Part A and Part B: Mean Residence Time (MRT)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Mean Residence Time (MRT)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Time delay between drug administration and the first observed concentration (tlag)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Time delay between drug administration and the first observed concentration (tlag)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Time of last quantifiable concentration (tlast)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.
Time frame: Part A: Day 1 to Day 2; Part B: Day 1 to Day 9
Part A1-Cohort 3: Time of last quantifiable concentration (tlast)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 to Day 4
Part A and Part B: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1 t2)]
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.
Time frame: Part A: Day 1; Part B: Day 1 and Day 7
Part A1-Cohort 3: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1 t2)]
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 and Day 3
Part A and Part B: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 - [fe(t1-t2)]
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.
Time frame: Part A: Day 1; Part B: Day 1 and Day 7
Part A1-Cohort 3: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 - [fe(t1-t2)]
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 and Day 3
Part A and Part B: Cumulative amount of unchanged drug excreted into urine (Aeinf)
To characterize the PK of AZD3974 following single and multiple ascending doses in healthy participants, including Chinese and Japanese participants.
Time frame: Part A: Day 1; Part B : Day 1 and Day 7
Part A1-Cohort 3: Cumulative amount of unchanged drug excreted into urine (Aeinf)
To assess the impact of food (fed) on the single-dose PK of AZD3974
Time frame: Day 1 and Day 3
Part B: Area under concentration time curve in the dosing interval (AUCtau)
To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants
Time frame: Day 1 to Day 9
Part B: Observed lowest concentration before the next dose is administered: (Ctrough)
To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 9
Part B: Accumulation ratio for AUC calculated as steady State AUCτ/First Dose AUCτ (Rac AUC)
To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants
Time frame: Day 1 to Day 9
Part B: Accumulation ratio for Cmax calculated as steady State Cmax/First Dose Cmax (Rac Cmax)
To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 9
Part B: Temporal change parameter calculated as steady State AUCτ/First Dose AUCinf (TCP)
To characterize the PK of AZD3974 following multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 9
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.